# Corcept Therapeutics Inc. (CORT) — Stock CV

Corcept Therapeutics Inc. is a $13.1B healthcare company. Revenue grew 16.0% over the last year, it keeps 7¢ of every dollar of sales as profit, and it holds more cash than debt. It trades at 237.4× earnings — near the highest of its own history.

> Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone.

## Identity

- **Ticker**: CORT
- **Sector**: Healthcare
- **Industry**: Pharmaceutical Preparations
- **Headquarters**: REDWOOD CITY, CA
- **Employees**: 730
- **Website**: https://www.corcept.com
- **Market cap**: $13.1B
- **Last price**: $121.19
- **Financial profile**: Strong

## Vitals (TTM)

- **Revenue**: $831M
- **Net income**: $55.2M
- **Free cash flow**: $107M
- **Net cash**: $366M
- **P/E**: 237.4
- **Revenue growth (YoY)**: 16.0%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 10 |
| Growth | 50 |
| Profitability | 55 |
| Health | 100 |
| Quality | 77 |
| Moat | 100 |

## Qualifications (beginner checklist) — 8 of 10 passed

- [x] Revenue growing — +16.0% YoY
- [x] Profitable — $55.2M TTM
- [ ] Profit growing — -1.7% YoY
- [x] Generates cash — $107M TTM
- [x] Debt under control — more cash than debt
- [x] Established company — $13.1B market cap
- [x] Not printing shares — -3.4% shares over ~5y
- [x] Proven track record — 10/10 profitable years
- [x] Financially stable — Altman Z 44.8 — safe
- [ ] Valuation not extreme — P/E 237.4

## Experience (career milestones)

- **FY2024** — Best year on record: $141M net income
- **FY2016** — Profitable every year on record: 10 consecutive profitable years in our data
- **FY2016** — Positive free cash flow every year since: 10-year streak

## Strengths

- High gross margin (98.3%)
- Revenue growing 16.0% year over year
- Net cash position after subtracting debt from cash
- Interest covered 106.6× by operating earnings
- High returns on invested capital (ROIC 35.4%)

## Watch-outs

- None stand out in the data.

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $366M | $113M | $167M |
| FY2022 | $402M | $101M | $120M |
| FY2023 | $482M | $106M | $127M |
| FY2024 | $675M | $141M | $196M |
| FY2025 | $761M | $99.7M | $142M |

---

Source: https://stockcv.com/CORT — derived from company filings; may be delayed or incomplete. Information, not investment advice.